Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 8Completed 8Active not recruiting 5Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 79Cisplatin 72Carboplatin 72Bevacizumab 29Radiotherapy 27Brachytherapy 23Hyperthermic Intraperitoneal Chemotherapy 20Drug Therapy 20olaparib 19Gemcitabine 17niraparib 16apatinib 16pembrolizumab 15Surgical Procedures, Operative 15liposomal doxorubicin 12Cyclophosphamide 12Surveys and Questionnaires 11camrelizumab 10Taxes 10Neoadjuvant Therapy 10fludarabine 9anlotinib 9Etoposide 9Blood Specimen Collection 9Topotecan 8Docetaxel 8Sentinel Lymph Node Biopsy 7Platinum 7Injections 7Cytoreduction Surgical Procedures 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × mirvetuximab soravtansine × Gynecologic × Clear all
NCT05622890 2022-11-21

A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3 Unknown
35 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡